MDXG MIMEDX GROUP, INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1376339 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-22.8%
TTM net income YoY-147.0%
TTM EPS YoY-148.1%
Revenue 3-yr CAGR-0.6%
Net income 3-yr CAGR—
Margins
Gross margin77.3%
Operating margin-8.3%
Net margin-6.3%
FCF margin—
EBITDA margin-3.5%
Returns
ROE-8.5%
ROA-6.6%
ROIC (approx.)-19.3%
Asset turnover1.04x
Leverage & solvency
Liabilities / assets20.2%
Debt / equity0.00x
Current ratio4.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.08x
Accruals ratio-13.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $62.28M | $64.36M | $58.99M | $118.09M | $113.72M | $98.61M | $88.20M | $92.91M |
| Cost of revenue | $12.58M | $19.98M | $17.37M | $19.05M | $18.72M | $18.68M | $16.56M | $16.91M |
| Gross profit | $49.70M | $44.38M | $41.62M | $99.04M | $95.01M | $79.92M | $71.65M | $76.00M |
| R&D expense | $2.80M | $2.78M | $4.14M | $4.76M | $3.70M | $3.30M | $3.33M | $3.57M |
| SG&A expense | $58.31M | $59.78M | $53.23M | $73.07M | $69.00M | $64.15M | $59.97M | $61.04M |
| Operating income | -$11.70M | -$18.47M | -$16.05M | $21.08M | $22.19M | $12.37M | $8.25M | $11.05M |
| Interest expense | — | — | $402,000 | $405,000 | $425,000 | $475,000 | $478,000 | $521,000 |
| Pretax income | -$11.06M | -$17.78M | -$15.33M | $21.80M | $22.85M | $13.01M | $8.61M | $11.25M |
| Income tax | -$2.38M | -$2.94M | -$4.47M | $6.60M | $6.10M | $3.39M | $1.59M | $3.81M |
| Net income | -$8.68M | -$14.84M | -$10.86M | $15.19M | $16.75M | $9.62M | $7.02M | $7.44M |
| EBITDA | -$11.33M | -$18.02M | -$15.52M | $34.27M | $22.76M | $12.93M | $8.81M | $11.62M |
| EPS (basic) | -0.06 | -0.10 | -0.07 | — | 0.11 | 0.07 | 0.05 | — |
| EPS (diluted) | -0.06 | -0.10 | -0.07 | — | 0.11 | 0.06 | 0.05 | — |
| Weighted avg. shares (diluted) | 145.87M | 147.80M | 148.45M | — | 149.71M | 149.32M | 149.68M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $120.79M | $135.84M | $159.77M | $166.12M | $142.08M | $118.87M | $106.43M | $104.42M |
| Receivables | $37.27M | $41.30M | $46.03M | $75.71M | $78.19M | $69.23M | $62.29M | $55.83M |
| Inventory | $22.09M | $20.93M | $26.23M | $25.34M | $26.50M | $24.89M | $24.07M | $23.81M |
| Current assets | $187.23M | $205.37M | $240.33M | $277.47M | $254.09M | $220.88M | $200.11M | $191.89M |
| PP&E, net | $4.71M | $4.91M | $4.76M | $4.71M | $5.00M | $5.39M | $5.77M | $5.94M |
| Goodwill | $19.44M | $19.44M | $19.44M | $19.44M | $19.44M | $19.44M | $19.44M | $19.44M |
| Intangibles | $11.12M | $12.09M | $13.14M | $14.16M | $11.15M | $12.03M | $11.06M | $11.63M |
| Total assets | $264.55M | $281.00M | $308.68M | $342.65M | $318.99M | $291.11M | $270.42M | $263.92M |
| Current liabilities | $43.03M | $38.50M | $44.55M | $64.27M | $57.68M | $50.29M | $42.62M | $45.59M |
| Short-term debt | $0 | $1.50M | $1.50M | $1.50M | $1.38M | $1.25M | $1.12M | $1.00M |
| Long-term debt | $0 | $15.71M | $16.09M | $16.47M | $16.84M | $17.21M | $17.53M | $17.83M |
| Total debt | $0 | $17.21M | $17.59M | $17.97M | $18.21M | $18.46M | $18.66M | $18.83M |
| Total liabilities | $53.47M | $65.00M | $65.74M | $86.11M | $80.04M | $74.48M | $67.64M | $70.81M |
| Shareholders' equity | $211.08M | $216.00M | $242.94M | $256.55M | $238.95M | $216.62M | $202.78M | $193.11M |
| Net debt | -$120.79M | -$118.63M | -$142.18M | -$148.15M | -$123.87M | -$100.41M | -$87.77M | -$85.59M |
| Shares outstanding | 145.93M | 145.72M | 148.93M | 148.09M | 148.08M | 147.92M | 147.61M | 146.93M |
| Cash flow statement | ||||||||
| Operating cash flow | $3.92M | -$10.02M | $1.88M | $24.96M | $29.33M | $14.42M | $5.30M | $18.78M |
| Investing cash flow | -$193,000 | -$635,000 | -$5.64M | -$335,000 | -$5.26M | -$887,000 | -$406,000 | -$2.77M |
| Financing cash flow | -$18.77M | -$13.28M | -$2.58M | -$583,000 | -$857,000 | -$1.09M | -$2.88M | -$400,000 |
| Depreciation & amortization | $370,000 | $441,000 | $528,000 | $13.19M | $572,000 | $558,000 | $558,000 | $564,000 |
| Stock-based compensation | $3.21M | $903,000 | -$1.70M | $2.46M | $4.92M | $4.75M | $4.26M | $4.69M |
| Share buybacks | $304,000 | — | — | $0 | $0 | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.